NeoPharm CO., LTD. (KOSDAQ:092730)

Market Cap	376.95B +28.1%
Revenue (ttm)	132.18B +11.1%
Net Income	27.82B +20.6%
EPS	1,778.81 +20.6%
Shares Out	15.64M
PE Ratio	13.55
Forward PE	11.76
Dividend	750.00 (3.55%)
Ex-Dividend Date	Dec 29, 2025

Volume	200,504
Open	23,800
Previous Close	24,100
Day's Range	23,750 - 25,500
52-Week Range	15,590 - 25,450
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 11, 2026

Data Sources Report a data error